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Summary Down-regulation of oncogene expression is one of the hallmarks of the process whereby
transformed cells are forced into differentiation and/or growth arrest by potent inducers and therefore can
represent an interim end point in cancer treatment. The differentiation inducer sodium butyrate (NaB) arrested
growth of N. 1 ovarian carcinoma cells and repressed expression ofcyclin D l/pradl and the invasiveness-related
protease plasminogen activator-urokinase (plau). This was accompanied by the acquisition of a differentiated
morphology, all of which characteristics were maintained as long as N.1 cells were exposed to the inducer. In
accordance with a differentiated phenotype was the finding that fibronectin expression was increased
significantly. Recently, it was shown that NaB represses the transcription factor c-myc by blocking Ca21 signals
and modulating serine threonine kinase activity. We wanted to investigate NaB-mediated interference on
signals contributing to the expression of pradl, plau and growth arrest-specific 6 (gas6). Protein kinase A
(PKA) inactivation de-repressed pradl and plau transcript levels. NaB had only general but no specific
influence on PKA-modulated pradl and plau expression however. Protein kinase C activation up-regulated plau
transcript levels, but not that of pradl. Pradl expression seemed to depend on Ca2+-triggered signals.
Constitutive plau expression was insensitive to additional Ca2+-mediated signals, but it became responsive
upon NaB treatment.
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Induction of cell differentiation has been discussed as a
therapeutic model in order to arrest cell growth (Bloch,
1984). The differentiation inducer retinoic acid is successfully
used in the treatment of the rare acute promyelocytic
leukaemia (Castaigne et al., 1990) and of squamous cell
carcinoma of the skin (Lippman et al., 1992). In vitro, the
human promyelocytic leukaemia cell line HL-60 as well as
keratinocytes could be terminally differentiated (Fischkoff et
al., 1990; Staiano-Coico and Higgins, 1992) and colon
carcinoma cells 'committed suicide' (Hague et al., 1993)
when exposed to the differentiation inducer sodium butyrate
(NaB). Novogrodsky et al. (1983) reported on a partial
remission of acute myelogenous leukaemia in a child that was
treated with NaB. We wanted to see what kind of effects NaB
might have on gene expression in an ovarian carcinoma cell
line, because ovarian carcinoma is the most lethal among
gynaecological malignancies and constant attempts to
develop new therapeutic concepts have to be undertaken.
The cell line N.1, which is a homogeneous, rapidly growing
subclone (Grunt et al., 1991) of the polyclonal ovarian
carcinoma cell line HOC-7 (Buick et al., 1985), has been
shown to be a particularly useful model in studying
differentiation inducers and morphogens. Upon induction
the small N.1 phenotype changes to a differentiated, big and
flattened morphology (Krupitza et al., 1995a). Concomi-
tantly, in response to NaB, c-myc is repressed.
We chose to investigate the constitutive and NaB-
modulated transcript levels of pradl/cyclin Dl, as there is
increasing evidence that the overexpression ofpradl is linked
to malignant transformation in man (Lukas et al., 1994;
Buckley et al., 1993; Jiang et al., 1993; Arnold et al., 1989).
In B-cell malignancies-specifically in mantle cell lymphomas
a typical t(I1;14) (ql3;q32) translocation juxtaposes the pradl
gene next to the IgH promoter/enhancer, which is among the
most active genes in B lymphocytes. Complex amplifications
occurring at 1q13 were also reported from breast, vulva,
spleen, lung, bladder and oesophageal carcinomas. It seems
that pradl overexpression is in part responsible for these
cancers, particularly in chronic types of leukaemias (Rabbitts,
1991). It was shown that the retinoblastoma gene product
(pRb) binds (and inactivates) pradl, which could conse-
quently block cell cycle progression (Dowdy et al., 1993).
Since a variety of additional transcription factors, cyclins and
(viral) oncogenes bind to pRb 'pockets' overrepresented
pradl might not be sequestered by an already 'saturated'
pRb. Thus pradl would remain activated.
The analysis of plasminogen activator-urokinase (plau),
seemed relevant to us, since there exists a direct correlation
between plau synthesis and invasive outgrowth (Montgomery
et al., 1993; Liotta et al., 1991; Axelrod et al., 1989). Upon
NaB treatment expression patterns of the cancer-related
genes pradl and plau were compared with those of the
differentiation-related genes growth arrest-specific 6 (gas6)
and fibronectin (FN).
The biochemical and molecular effects during NaB
exposure in an intact cell are multiple (Krupitza et al.,
1995b). We tried to elucidate mechanisms of NaB-dependent
interactions on gene expression by an approach of
simultaneous interference with macromolecule synthesis
(transcription and translation) and intracellular signal
generation, thereby also learning more about the general
regulation of the analysed genes in ovarian carcinoma cells.
Material and methods
Chemicals and probes
pradl cDNA was a gift from Dr Hannes Hofmann, Cold
Spring Harbor Labs, NY, USA; gas6 (growth arrest-specific
6) was generously provided by Dr Claudio Schneider,
ICGEB, Trieste, Italy; and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) cDNA was donated by Dr Paul
Amstad, ISREC, Lausanne, Switzerland. The cDNA of
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plasminogen activator-urokinase (ATCC, no. 57329) and of
fibronectin (ATCC, no. 61039) was purchased from the
American Type Culture Collection (Rockville, MD, USA).
Phorbol 12-myristate 13-acetate (TPA; used at a final
concentration of 10 gg ml-'), cyclohexamide (used at a final
concentration of 10 ,ug ml-'), actinomycin D (used at a final
concentration of 50 gg ml-'), forskolin (used at 10 ,UM final
concentration) and NaB (used at concentrations indicated in
the text) were purchased from Sigma (St Louis, MO, USA),
thapsigargin (used at a final concentration of 1 gg ml-') was
from Calbiochem (San Diego, CA, USA) and H-89, which is
a specific inhibitor of protein kinase A, (used at 0.5 gM final
concentration) was from Seikagaku Corporation (Tokyo,
Japan).
Cell culture and experimental manipulations
N.1 cells were grown in alpha-minimal essential medium
(MEM) supplemented with 10% heat-inactivated fetal calf
serum (Gibco, Paisley, UK) at 37°C in a humidified
atmosphere containing 5% carbon dioxide. Actinomycin D
and cyclohexamide were routinely added (at concentrations
given above), either alone or in combination with 3.5 mM
NaB for 3 h only, to avoid gene expression biased by
pharmacotoxicity. Since it took considerable time until plau
expression responded to NaB exposure N.1 cells were
preincubated with NaB for 4 h and then the signal
transduction modulators H-89, forskolin, TPA and thapsi-
gargin were added (at concentrations given above) and the
experiments allowed to continue for another 3 h.
Northern blot analysis
Cell monolayers were rinsed with ice-cold PBS (phosphate-
buffered saline pH 7.2), then cells were covered with
RNAzolTM (BioTex, Houston, TX, USA) and RNA
a
C
0 0
isolated according to the instructions. A total of 30 jg of
RNA per lane was electrophoretically separated on a
9
co 0
x
a)
7
5
3
Control
9
Time (days)
Figure 1 Inhibition of N.1 proliferation by increasing concentra-
tions of sodium butyrate (NaB). For each point measured 5 x 104
cells were seeded into T-25 culture flasks. Cells were allowed to
grow for 3 days, then NaB was added (indicated by an arrow) at
final concentrations of 2.0mM (X), 3.0mM (0) and 4.5mM (0).
One set ofN.1 cells was allowed to grow unaffected and served as
control (N). Cells were removed from the culture device with
trypsin after 2, 3, 5, 7 and 9 days and the number was counted.
The x-axis shows the time in days of incubation, the y-axis the
amount of cells per T-25 flask. The data of one representative
experiment are shown.
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Figure 2 (a) Response ofpradl and plau mRNA to increasing doses of NaB. Lane Control: constitutive expression of untreated
N.1 cells. Lanes 0.5-4.5: N.l cells were exposed for 72h to 0.5, 2.0, 3.0 and 4.5mm NaB respectively. (b) Kinetic of NaB-modulated
expression ofpradl, plau and FN transcripts. Lane Control: constitutive expression of untreated N. 1 cells. Lanes 1-24: N. 1 cells
were exposed to 3.5mm NaB for 1, 3, 8 and 24h respectively. Filters were hybridised against pradl (upper panels), stripped and
rehybridised against plau (middle panels), restripped and rehybridised with a GAPDH probe alone (a) or simultaneously with
probes against GAPDH and FN (b).
prad 7 -
plau -*
GAPDH-Butyrate represses cancer-related genes
G Krupitza et al 4
formaldehyde-containing agarose gel and transferred to nylon
filters. Probe biotinylations, filter development, using
PolarPlex labelling and detection kits (Millipore, Bedford,
MA, USA) and image processing were done exactly as
described before (Krupitza et al., 1995c).
Results
NaB exposure andproliferation
Concentrations of 3.0 mM and 4.5 mM NaB entirely blocked
proliferation, whereas 2.0 mM NaB still allowed growth at a
reduced rate (Figure 1). Induction of death (programmed or
by toxicity) was not observed when cells were analysed and
counted under the microscope.
NaB exposure and pradl/cyclin Dl expression
Substantial morphological changes could be observed when
N.1 cells were exposed to NaB for 3 days. At this time total
RNA was isolated and pradl mRNA expression analysed by
Northern blotting. Figure 2a (panel 1) shows that NaB
concentrations above 0.5 mM (lane 2) suppressed pradl
transcript levels. In subsequent experiments 3.5 mM NaB
was used. This concentration yielded maximal morphological
effects, inhibited proliferation and was still non-toxic. After
exposing N.1 cells to 3.5 mM NaB, pradl mRNA expression
was significantly suppressed after 3 h (Figure 2b, panel 1,
lane 3) and reached a minimum after 24 h (lane 5). The rapid
decrease of pradl transcripts upon NaB treatment implied
high mRNA turnover, which was confirmed on the basis of
cyclohexamide (CX) co-application.
Addition of CX resulted in pradl mRNA accumulation
(Figure 3b, lane 2), thus, rapid pradl transcript degradation
required de novo protein synthesis. This is also the case for
immediate-early genes such as c-fos (Amstad et al., 1992) and
c-myc (Marcu et al., 1992). Since pradl is a cyclin, we
analysed the mRNA expression throughout the cell cycle.
Neither in synchronised nor in non-synchronised cells were
pradl transcripts observed to oscillate (data not shown).
Lukas et al. (1994) reported that pradl protein synthesis is
stringently connected to the mRNA levels, therefore pradl
expression is mainly under transcriptional control. Addition
of actinomycin D (AD) alone had no effect on pradl
transcript levels (Figure 3b, lane 3).
gas6 mRNA levels dropped (Figure 3a) rather than
increased-although cells arrested growth.
The instability of the gas6 transcripts involved de novo
protein synthesis, as shown by CX-induced mRNA
accumulation (Figure 3b, lane 2). Exposure of N.1 cells to
NaB for only 3 h had no effect on gas6 expression, (lane 1 vs
lane 5).
Protein kinase A (PKA) dependent signalling
The distinct kinetics of pradl and plau down-regulation by
NaB (Figure 2b) supported the idea that the mechanisms by
which transcriptional repression was achieved might be
different. One possibility for alternative gene regulation
could be based on the fact that different signal transduction
pathways controlled the steady-state expression of the genes
under investigation.
Constitutive levels of pradl (Figure 4a, lane 1) increased
when the activity of cAMP-dependent PKA was blocked by
H-89 (lane 3). Just as for pradl, constitutive plau expression
in N.1 cells was clearly co-controlled by PKA, because H-89
treatment resulted inplau over-expression (Figure 4a, lane 3).
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NaB exposure and plau expression
Transcript levels ofplau were maximally suppressed between
3.0 nd 4.5 mM NaB when analysed after 3 days' treatment
(Figure 2a, panel 2). Exposure of N.1 cells to NaB had to
exceed 3 h to achieve repression ofplau mRNA levels (Figure
2b, panel 2, lane 4). Before down-regulation, a slight increase
of plau transcript levels was observed for reasons which
remain obscure (Figure 2b, panel 2, lane 3). Upon CX
treatment plau mRNA accumulated (not shown).
Fibronectin (FN), known to play a positive role during
differentiation (Ruoslahti, 1988), was analysed in N.1 cells
upon 3.5 mM NaB treatment.
Figure 2b (panel 3) shows that FN transcript levels were
dramatically increased after 8 h of exposure to the
differentiation inducer.
NaB exposure and the gene growth arrest-specific 6 (gas6)
NIH 3T3 cells that are growth arrested by serum deprivation
start to synthesise gas6 (Schneider et al., 1988), which is a
vitamin K-dependent gene suspected to participate in growth
control (Manfioletti et al., 1993). N.1 cells constitutively
express gas6 and the mRNA accumulates when N.1 cells
become confluent and retard growth (unpublished observa-
tion). In an inverse analogy, when c-myc from N.1 cells is
induced by mitogens and starts to replicate DNA
(unpublished observation), gas6 levels drop as expected.
However, upon a 3 day treatment with 2.0-4.5 mM NaB
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Figure 3 (a) Response of gas6 mRNA to increasing doses of
NaB. Lane Control: Constitutive expression of untreated N.1
cells. Lanes 0.5-4.5: N.1 cells were exposed for 72h to 0.5, 2.0,
3.0 and 4.5mm NaB respectively. (b) Constitutive and NaB-
modulated pradl and gas6 transcript expression is affected by
cyclohexamide and actinomycin D in N.1 cells. CO, Constitutive
mRNA expression. NaB, N.1 cells treated with 3.5mM NaB for
3h either alone, or in combination with cyclohexamide (CX),
actinomycin D (AD) or both (CX+AD). Filters were hybridised
simultaneously against gas6 and pradl (upper panels), stripped
and rehybridised with a probe against GAPDH (lower panels).Butyrate represses cancer-related genes
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Figure 4 PKA modulators (a) and tumour promoters (b) influence constitutive and NaB-suppressed transcript levels ofpradl, plau
and gas6 in N.1 cells. Untreated N. 1 cells (-) and N.1 cells that were pretreated with 3.5 mM NaB (+) for 4h were subsequently
exposed (still in the presence of NaB) to the PKA inhibitor H-89, the adenylate cyclase activator forskolin, the PKC activator TPA
and thapsigargin, which is a modulator of intracellular Ca2 , for another 3h, or left unexposed (Control). The isolated RNA was
hybridised against pradl and gas6 simultaneously (upper panels), stripped, rehybridised against plau (middle panels), restripped and
rehybridised with a probe against GAPDH (lower panels).
Thus, PKA activity suppressed pradl. Accordingly, when
PKA was stimulated by forskolin (which is an inducer of
adenylate cyclase and therefore increases the cAMP pool, the
substrate of PKA) suppression of constitutive pradl and plau
levels were observed (lane 5). When NaB was given in
addition to H-89 and forskolin respectively, pradl transcript
levels were down-regulated without indicating NaB-specific
regulation on PKA-dependent signalling. When NaB was
given in the presence of forskolin, however, no suppression of
plau transcripts was observed (lane 6).
PKC and Ca2"-dependent signalling
TPA (Figure 4b, lane 3) neither influenced constitutive (lane
1) nor NaB-mediated down-regulation of pradl (lane 4).
Constitutive plau expression (lane 1, panel 2) was dramati-
cally induced by TPA (lane 3). NaB, which down-regulated
steady-state plau mRNA (lane 2), was entirely ineffective in
modulating TPA-mediated overexpression ofplau transcripts
(lane 4).
Thapsigargin induces Ca2+ release from intracellular stores
(Clapham, 1995). Unexpectedly, thapsigargin slightly de-
creased, rather than elevated constitutive pradl mRNA
levels (Figure 4b, lane 5) and co-application of NaB further
reduced transcript expression (lane 6).Thus, interference of
NaB on pradl expression was apparently not specific to early
Ca2+ signals.
Thapsigargin had no effect on constitutive plau mRNA
levels (Figure 4b, panel 2, lane 5). NaB administered alone
down-regulated plau mRNA expression (lane 2). In contrast,
co-application of NaB and thapsigargin resulted in plau
transcript accumulation (lane 6).
The differentiating effect is not terminal: as soon as NaB
was removed from the culture medium the transcripts of the
investigated genes reappeared and were re-expressed within
12 h.
FN mRNA levels also dropped (Figure 5) when NaB was
removed. Thereafter cells changed their morphology to the
N.1 phenotype and resumed growing (Krupitza, 1995b).
Discussion
The following conclusions can be drawn from this study.
pradl is efficiently down-regulated by NaB exposure. The
transcript required de novo mRNA synthesis for degradation
otherwise pradl levels should have decreased during
inhibition of transcription. This, however, might only be
achieved when a pradl mRNA controlling gene is synthesised
(in terms of both transcription and translation) even earlier
than pradl itself. Both exposure to CX alone or co-
application of CX and AD, resulted in pradl mRNA
accumulation, suggesting that pradl transcript instability
required de novo translation of another-probably unstable
and even earlier -gene for its regulation. Recent work by
Daksis et al. (1994) identified the c-myc protein as a regulator
of the pradl oncogene in Rat. cells. c-myc itself is an
immediate-early gene with a very short-lived transcript and
protein. Moreover it was found that NaB promotes c-myc
instability (Herold and Rothberg, 1988; Krupitza et al.,
1995b), which might finally result in pradl down-regulation
by NaB.
TPA, which induces c-myc (Krupitza et al., 1995b) in N.1
cells, failed to induce pradl, however, implying a more
complex c-myc-pradl relationship.
In the same way as pradi, plau was repressed by NaB.
Addition of AD, either alone or in combination with CX,
kept plau mRNA at control levels, whereas CX alone resulted
in transcript accumulation (data not shown). Thus, plau and
pradl mRNA degradation by NaB seemed to be controlled
by distinct mechanisms.
The data suggested that gas6 did not exert direct growth
control on N.1 cells, because gas6 was down-regulated in
consequence to NaB-mediated growth arrests. In contrast,
high gas6 levels measured in resting cells following serum
deprivation (Schneider et al., 1988; G Krupitza, unpublished
observation), might indicate the existence of different types of
cell cycle arrest conducted by independent genes.
PKA down-regulated constitutive as well as NaB-
modulated expression of pradl and plau. NaB, however, did
a
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Figure 5 Release from the NaB arrest. N.1 cells were exposed to
3.5 mm NaB for 3 days (Arrest), then the culture medium was
discarded, monolayers were rinsed once with prewarmed PBS and
were further incubated in the presence of standard medium
containing 10% FCS for 2, 4 and 12h respectively. The filter
carrying separated total RNA of N.1 cells was hybridised against
pradi and gas6, stripped, rehybridised againstplau, restripped and
rehybridised against EN and GAPDH.
not specifically interact with PKA signalling. Adenylate
cyclase contributed to plau expression, but not across PKA
activation. Since we did not observe plau suppression when
NaB was applied in the presence of forskolin, maintenance of
plau transcript levels might be accomplished by a separate
signalling pathway that either (co-)controlled plau in parallel
to the PKA pathway, just enforced by NaB, or which became
immediately switched on upon NaB treatment.
PKC activity regulated expression ofplau, but not that of
prad]. The experiments using TPA supported the idea that
NaB had no direct influence on PKC activity. Previous
experiments, however, clearly showed that TPA-mediated c-
myc induction could be blocked by co-application of NaB
(Krupitza et al., 1995b).
Thus it can be concluded that signals, which are initially
generated by, or transduced across PKC, are blocked by NaB
somewhere downstream of an unidentified checkpoint, at
which signals split up for selected target genes.
Ca2+ release from intracellular stores influenced pradl
expression more in general rather than specifically. plau,
which was initially not regulated by Ca2"-mediated signalling
(thapsigargin exposure had no effect on plau expression)
became sensitive to such signals during NaB treatment
(thapsigargin in combination with NaB resulted in transcript
accumulation). This could either be achieved by
(i) improved accessibility of plau promoter regions (by
loosening respective chromatin structures by NaB-mediated
histone hyper-acetylation; (Lee et al., 1993);
(ii) by inhibition of transcription suppressors; or
(iii) by stimulation of transcription promoters that are
capable of co-operating with Ca2"-induced signals.
The results described above demonstrate that the effects of
even well-characterised bioactive agents on gene expression
are unpredictible when applied in combination. Compounds
that additively or synergistically repress growth-related genes
might oppose repression of genes involved in invasive
outgrowth.
There existed a small minority of cells that became
multinucleated upon NaB treatment, exhibiting a tremen-
dous increase in plasma mass (giants). Leakiness of NaB on
cell cycle specific growth arrest in G1 permits a minority to
arrest as late as G2 (Karlsen et al., 1991). This fact might
have resulted in nuclear division, but not in cytokinesis
(Krupitza et al., 1995b). We have not observed that these
cells re-entered the cell cycle. Although these cells cannot be
classified as 'terminally differentiated' (in a functional sense),
they were probably stably arrested. However, the vast
majority of cells was only reversibly blocked (depending on
the presence of NaB).
Since NaB induces efficient growth arrest at non-toxic
concentrations, the compound might be utilised to study
effects on growth factor receptor regulation.
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